5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
BACKGROUND and AIMS: This study was performed to quantify the risk of renal disease in patients using aminosalicylates (5-ASA). METHODS: Data from the United Kingdom General Practice Research Database were used to estimate the incidence of renal disease in adult patients with inflammatory bowel dis...
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
2004
|
| _version_ | 1826268876684394496 |
|---|---|
| author | Van Staa, T Travis, S Leufkens, H Logan, R |
| author_facet | Van Staa, T Travis, S Leufkens, H Logan, R |
| author_sort | Van Staa, T |
| collection | OXFORD |
| description | BACKGROUND and AIMS: This study was performed to quantify the risk of renal disease in patients using aminosalicylates (5-ASA). METHODS: Data from the United Kingdom General Practice Research Database were used to estimate the incidence of renal disease in adult patients with inflammatory bowel disease (IBD) or prescription for 5-ASA and in patients without IBD. In a nested case-control analysis, each case of renal disease was matched to 5 controls. RESULTS: Among the 19,025 5-ASA users with IBD, 130 patients developed renal disease (incidence rate of 0.17 cases per 100 patients per year). The incidence among patients with IBD but without 5-ASA use was 0.25 and among patients without IBD was 0.08. In the case-control analysis, the crude odds ratio (OR) for renal disease in current 5-ASA users was 1.60 (95% confidence interval [95% CI]: 1.14-2.26); the adjusted OR was 0.86 (95% CI: 0.53-1.41). For recent users, the crude OR was 4.18 (95% CI: 2.59-6.76) and adjusted OR 2.48 (95% CI: 1.33-4.61); for past users (last prescription more than 12 months before), 1.71 (95% CI: 1.09-2.70) and 0.99 (95% CI: 0.55-1.76), respectively. Although the numbers were small, mesalazine and sulfasalazine users had comparable risks (crude OR for current and recent users of OR 2.08 [95% CI: 1.44-3.01] and 1.84 [95% CI: 1.20-2.82], respectively). In only a few records was renal disease attributed to interstitial nephritis or 5-ASA use. CONCLUSIONS: Users of 5-ASA have an increased risk of renal disease that may be partly attributable to the underlying disease. Although renal disease is a recognized adverse effect of 5-ASA, the incidence appears to be low and does not appear to be related to either the dose or type of 5-ASA used. |
| first_indexed | 2024-03-06T21:16:18Z |
| format | Journal article |
| id | oxford-uuid:3fe787bb-8fa0-4a57-b38c-a75f4b2e3864 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:16:18Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:3fe787bb-8fa0-4a57-b38c-a75f4b2e38642022-03-26T14:34:50Z5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3fe787bb-8fa0-4a57-b38c-a75f4b2e3864EnglishSymplectic Elements at Oxford2004Van Staa, TTravis, SLeufkens, HLogan, R BACKGROUND and AIMS: This study was performed to quantify the risk of renal disease in patients using aminosalicylates (5-ASA). METHODS: Data from the United Kingdom General Practice Research Database were used to estimate the incidence of renal disease in adult patients with inflammatory bowel disease (IBD) or prescription for 5-ASA and in patients without IBD. In a nested case-control analysis, each case of renal disease was matched to 5 controls. RESULTS: Among the 19,025 5-ASA users with IBD, 130 patients developed renal disease (incidence rate of 0.17 cases per 100 patients per year). The incidence among patients with IBD but without 5-ASA use was 0.25 and among patients without IBD was 0.08. In the case-control analysis, the crude odds ratio (OR) for renal disease in current 5-ASA users was 1.60 (95% confidence interval [95% CI]: 1.14-2.26); the adjusted OR was 0.86 (95% CI: 0.53-1.41). For recent users, the crude OR was 4.18 (95% CI: 2.59-6.76) and adjusted OR 2.48 (95% CI: 1.33-4.61); for past users (last prescription more than 12 months before), 1.71 (95% CI: 1.09-2.70) and 0.99 (95% CI: 0.55-1.76), respectively. Although the numbers were small, mesalazine and sulfasalazine users had comparable risks (crude OR for current and recent users of OR 2.08 [95% CI: 1.44-3.01] and 1.84 [95% CI: 1.20-2.82], respectively). In only a few records was renal disease attributed to interstitial nephritis or 5-ASA use. CONCLUSIONS: Users of 5-ASA have an increased risk of renal disease that may be partly attributable to the underlying disease. Although renal disease is a recognized adverse effect of 5-ASA, the incidence appears to be low and does not appear to be related to either the dose or type of 5-ASA used. |
| spellingShingle | Van Staa, T Travis, S Leufkens, H Logan, R 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. |
| title | 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. |
| title_full | 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. |
| title_fullStr | 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. |
| title_full_unstemmed | 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. |
| title_short | 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. |
| title_sort | 5 aminosalicylic acids and the risk of renal disease a large british epidemiologic study |
| work_keys_str_mv | AT vanstaat 5aminosalicylicacidsandtheriskofrenaldiseasealargebritishepidemiologicstudy AT traviss 5aminosalicylicacidsandtheriskofrenaldiseasealargebritishepidemiologicstudy AT leufkensh 5aminosalicylicacidsandtheriskofrenaldiseasealargebritishepidemiologicstudy AT loganr 5aminosalicylicacidsandtheriskofrenaldiseasealargebritishepidemiologicstudy |